Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
cSCC is one of the most common cancers in the U.S. and globally
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
This year, the OCTF focused on preparing a white paper on oral cancer elimination in India and updating its annual consensus guidelines
This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases
Subscribe To Our Newsletter & Stay Updated
